Muscle Stem Cell Quality in Atrophy

Launched by MAASTRICHT UNIVERSITY MEDICAL CENTER · Oct 5, 2023

Keywords

ClinConnect Summary

This clinical trial, titled "Muscle Stem Cell Quality in Atrophy," is studying the quality of certain muscle stem cells called mesoangioblasts in people who have muscle weakness or atrophy, which can occur due to conditions like cancer or aging. The researchers want to see if these stem cells from different patient groups can be used effectively for future treatments. Participants will be divided into groups based on their health status, including those with cancer-related muscle loss, older adults with muscle issues, and a control group of similar age without these issues.

To participate, individuals should be aged 50 to 80 and meet specific health criteria, such as having a diagnosis of advanced lung cancer with muscle loss or needing surgery for hip, knee, or back issues. During the study, participants will undergo a small muscle biopsy, donate a small amount of blood, and complete two questionnaires about their physical activity and muscle health. This information will help researchers understand the differences in muscle stem cell quality among the various groups, which could lead to new treatment options for muscle weakness in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Lung cancer cachexia:
• • Diagnosed with NSCLC, stage III-IV
• • Diagnosed with cachexia (\>5% unintentional body weight loss in past six months, \>2% body weight loss with BMI \<20, or skeletal muscle index for males \<7.26 kg/m2; females \<5.45 kg/m2)
• • Age 50-60 or 60-70
• • Written informed consent
• • Patient group: MIE
• • Scheduled for total hip, knee, or back surgery
• • Age 60-70 or 70-80 year
• • Written informed consent
• • Controls
• • Patients with scheduled knee-, hip-, and back surgery
• • Age 50-60, 60-70, and 70-80 year
• • Age and sex-matched to patient groups
• • Written informed consent
• Exclusion Criteria:
• • No filled-in IC
• • Suffering from a muscular dystrophy or other disease known to affect muscle morphology or function
• • Have a weekly alcohol intake of ≥ 35 units (men) or ≥ 24 units (women)
• • Ongoing participation in other intervention clinical trials
• • Major surgery of the muscle within 4 weeks of the visit unrelated to the study
• • Patients unable and/or unwilling to comply with treatment and study instructions
• • Any other factor that in the opinion of the investigator excludes the patient from the study